AZD2171 to treat children and adolescents with solid tumours or acute myelogenous leukemia
- Conditions
- Refractory or recurrent solid tumours or acute myelogenous leukemiaMedDRA version: 14.1Level: LLTClassification code 10049280Term: Solid tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
- Registration Number
- EUCTR2012-001155-39-Outside-EU/EEA
- Lead Sponsor
- AstraZeneca AB
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- A
- Sex
- All
- Target Recruitment
- 40
Patients must be greater than 2 and less than 19 years of age
Solid tumours: histologically confirmed extracranial malignant solid tumours
Leukemia : histologically confirmed acute AML
Patients cancer must have relapsed after or failed to respond to frontline standard therapy and no other standard curative treatment options are available
Are the trial subjects under 18? yes
Number of subjects for this age range:
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Patients with primary brain tumours, active CNS metastasis, or active spinal cord metastasis or compression. AML patients with CNS leukemia.
Patients receiving medication for treatment of hypertension or patients with a diastolic blood pressure 5mmHg greater than the 95% for gender and age on 3 measurements
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method